{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:06Z","timestamp":1792788546156,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.annonc.2023.10.123","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T18:03:53Z","timestamp":1702145033000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors"],"prefix":"10.1016","volume":"35","author":[{"given":"K.D.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Migden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-Y.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-F.","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hernandez-Aya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Seebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Fury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2023.10.123_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"key":"10.1016\/j.annonc.2023.10.123_bib2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/aje\/kwt073","article-title":"Basal-cell carcinoma incidence and associated risk factors in US women and men","volume":"178","author":"Wu","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.annonc.2023.10.123_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","article-title":"Advanced basal cell carcinoma: epidemiology and therapeutic innovations","volume":"3","author":"Mohan","year":"2014","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.annonc.2023.10.123_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/CRT.1000231","article-title":"Targeted therapies in the treatment of advanced basal cell carcinoma","volume":"4","author":"Migden","year":"2018","journal-title":"Clin Res Trials"},{"key":"10.1016\/j.annonc.2023.10.123_bib5","first-page":"129","article-title":"Advanced basal cell carcinoma, the hedgehog pathway, and treatment options\u2014role of smoothened inhibitors","volume":"9","author":"Fecher","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.annonc.2023.10.123_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejca.2013.12.013","article-title":"Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease","volume":"50","author":"McCusker","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2016.02.021","article-title":"Hedgehog pathway inhibition","volume":"164","author":"Sekulic","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2023.10.123_bib8","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.123_bib9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.123_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.18632\/oncotarget.28080","article-title":"Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma","volume":"12","author":"Doan","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2023.10.123_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: results from an open-label, phase 2, single-arm trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.123_bib15","unstructured":"ClinicalTrials.gov PD-1 in patients with advanced basal cell carcinoma who experienced progression of disease on hedgehog pathway inhibitor therapy, or were intolerant of prior hedgehog pathway inhibitor therapy. 2022. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03132636. Accessed March 3, 2023."},{"key":"10.1016\/j.annonc.2023.10.123_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.annonc.2023.10.123_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-Seguin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamadermatol.2015.5473","article-title":"Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma","volume":"152","author":"Ally","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2017.11.031","article-title":"An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas","volume":"78","author":"Tran","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study","volume":"80","author":"Chang","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/npjgenmed.2016.37","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy","volume":"1","author":"Ikeda","year":"2016","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.annonc.2023.10.123_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.123_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2015.11.007","article-title":"Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma","volume":"2","author":"Mohan","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annonc.2023.10.123_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annonc.2023.10.123_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.annonc.2023.10.123_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.123_bib31","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2023.10.123_bib32","first-page":"1","article-title":"Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy","volume":"40","author":"Hall","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423043296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423043296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:02:24Z","timestamp":1760338944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423043296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0923753423043296"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.123","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}